Centrum Medyczne Luxmed Sp. z o.o.

The Centrum Medyczny Luxmed site in Lublin concentrates on clinical research in psychiatry and psychology, addressing major mood and psychotic conditions. Current studies evaluate innovative treatments for major depressive disorder, including variants with severe anhedonia, as well as adjunctive strategies for refractory schizophrenia and treatment‑resistant schizophrenia. The primary goal is to determine safety, tolerability, and therapeutic benefit for patients with persistent mental health challenges.

• Major Depressive Disorder (MDD)
• MDD with Moderate‑to‑Severe Anhedonia
• Refractory Schizophrenia
• Treatment‑Resistant Schizophrenia (TRS)

Ongoing trials feature long‑term safety assessments of a kappa‑opioid receptor antagonist, adjunctive agents such as aticaprant and NBI‑1065845 for relapse prevention, and dose‑response investigations of NaBen® combined with clozapine. Another study examines evenamide as an add‑on therapy for patients who do not respond to standard antipsychotics. Together, these efforts aim to broaden therapeutic options and improve outcomes for individuals living with chronic depressive or psychotic disorders.